natgillin/translations-raw huggingface dataset:
Ibandronic acid Accord 3 mg solution for injection in pre-filled syringe must not be mixed with calcium-containing solutions (such as Ringer-Lactate solution, calcium heparin) or other intravenously administered medicinal products. 
Zdravila Ibandronska kislina Accord 3 mg raztopina za injiciranje v napolnjeni injekcijski brizgi ne smemo mešati z raztopinami, ki vsebujejo kalcij (kot je raztopina Ringerjevega laktata, kalcijev heparin) ali drugimi intravensko dajanimi zdravili.
The number of SREs was also significantly reduced with ibandronic acid 6 mg and there was a 40% reduction in the risk of a SRE over placebo (relative risk 0.6, p = 0.003). 
Pri bolnikih, zdravljenih z ibandronsko kislino 6 mg, je bilo število SRE značilno zmanjšano, tveganje za nastanek SRE pa 40 % manjše (relativno tveganje 0,6, p = 0,003) v primerjavi s placebom.
See also dose section above for patients with renal impairment. 
Glejte tudi zgornje poglavje o odmerjanju pri bolnikih z ledvično okvaro.
Chemical and physical in-use stability after dilution in 9 mg/ml (0.9 %) sodium chloride solution or 5% glucose solution has been demonstrated for 36 hours at 25°C and 2°C to 8°C. 
Kemična in fizikalna stabilnost po razredčitvi v 9 mg/ml (0,9 %) raztopini natrijevega klorida ali 50 mg/ml (5 %) raztopini glukoze je bila dokazana za 36 ur pri 25 °C in 2 °C do 8 °C.
Furthermore, ibandronic acid 3 mg injection every 3 months was proven superior to oral ibandronic acid 2.5 mg daily for increases in lumbar spine BMD in a prospectively planned analysis at one year, p<0.001, and at two years, p<0.001. 
Ibandronska kislina 3 mg v obliki injekcije, dane vsake 3 mesece, se je izkazalo za boljše kakor peroralno dana ibandronska kislina 2,5 mg enkrat na dan v povišanju MKG ledvene hrbtenice v prospektivno načrtovani analizi po enem letu, p < 0,001, in dveh letih, p < 0,001.
• Talk to your doctor if you have ear pain, discharge from the ear, and/or an ear infection. 
• v primeru bolečine v ušesu, izcedka iz ušesa in/ali okužbe ušesa se posvetujte s svojim zdravnikom.
Pre-filled syringes made of colourless glass, the grey plunger rubber stopper and tip cap, containing 3 ml of solution for injection. 
Napolnjene injekcijske brizge iz brezbarvnega stekla s sivim gumijastim zamaškom bata in zaporko; vsebujejo 3 ml raztopine za injiciranje.
If a dose is missed, the injection should be administered as soon as convenient. 
Če bolnik odmerek izpusti, mu je treba injekcijo dati takoj, ko je mogoče.
Hypersensitivity†, bronchospasm†, angioedema† anaphylactic reaction/shock† 
Bolezni imunskega sistema preobčutljivost†, bronhospazem†, angioedem†, anafilaktična reakcija/šok†**
The safety and efficacy of ibandronic acid in children and adolescents below the age of 18 years have not been established. 
Varnost in učinkovitost ibandronske kisline pri otrocih in mladostnikih, starih manj kot 18 let, nista bili dokazani.
Increases at the hip compared to baseline were 2.8 % at the femoral neck, 3.4 % at the total hip, and 5.5 % at the trochanter. 
V primerjavi z izhodiščno vrednostjo je porast mineralne kostne gostote znašal za stegnenični vrat 2,8 %, za kolk 3,4 % in 5,5 % za trohanter.
It is supplied as packs containing 1 vial with 2 ml of concentrate. 
Na voljo je v škatlah, v katerih je 1 viala z 2 ml koncentrata.
On the basis of the pharmacodynamic and pharmacokinetic profile and reported adverse reactions, it is expected that ibandronic acid has no or negligible influence on the ability to drive and use machines. 
Glede na farmakodinamske in farmakokinetične lastnosti ter poročane neželene učinke pričakujemo, da ibandronska kislina nima ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Ibandronic acid Accord is prescribed to you to treat postmenopausal osteoporosis because you have an increased risk of fractures. 
Zdravilo Ibandronska kislina Accord vam je zdravnik predpisal za zdravljenje pomenopavzne osteoporoze, ker imate povečano tveganje za zlome.
• mouth ulcers, swollen lips (‘“cheilitis”'), oral thrush 
• ustne razjede, otekle ustnice (heilitis), ustni oprh;
• a heart rhythm problem called ‘“bundle branch block”' 
• težava s srčnim ritmom, imenovana kračni blok,
What Ibandronic acid Accord is and what it is used for 2. 
Kaj je zdravilo Ibandronska kislina Accord in za kaj ga uporabljamo 2.
Based on knowledge of this class of compounds, intravenous overdosage may result in hypocalcaemia, hypophosphataemia, and hypomagnesaemia. 
Glede na podatke o tej skupini zdravil lahko preveliko intravensko odmerjanje povzroči hipokalcemijo, hipofosfatemijo in hipomagnezemijo.
For patients with mild renal impairment (CLcr ≥50 and <80 ml/min) no dosage adjustment is necessary. 
Pri bolnikih z blago ledvično okvaro (CLcr ≥ 50 in < 80 ml/min) prilagajanje odmerkov ni potrebno.
What Ibandronic acid Accord looks like and contents of the pack Ibandronic acid Accord is a concentrate for solution for infusion (sterile concentrate). 
Izgled zdravila Ibandronska kislina Accord in vsebina pakiranja Zdravilo Ibandronska kislina Accord je koncentrat za raztopino za infundiranje (sterilni koncentrat).
Based on knowledge of this class of compounds, intravenous overdosage may result in hypocalcaemia, hypophosphataemia, and hypomagnesaemia, which can cause paraesthesia. 
Glede na poznavanje te skupine učinkovin, se lahko intravensko preveliko odmerjanje kaže v hipokalcemiji, hipofosfatemiji in hipomagnezemiji, kar lahko povzroči parestezijo.
For patients with breast cancer and bone metastases, Ibandronic acid Accord infusion should be administered every 3-4 weeks. 
Bolniki z rakom dojke in metastazami v kosteh morajo prejeti infuzijo zdravila Ibandronska kislina Accord vsake 3 do 4 tedne.
SMPR (per patient year) 
SMPR (na bolnikovo leto) 1,48
The pharmacodynamic action of ibandronic acid is inhibition of bone resorption. 
Farmakodinamični učinek ibandronske kisline je zaviranje resorpcije kosti.
Clinical studies have not shown any evidence of deterioration in renal function with long term ibandronic acid therapy. 
Klinične študije niso pokazale, da bi pri dolgotrajnem zdravljenju z ibandronsko kislino prišlo do poslabšanja ledvične funkcije.
Renal clearance of ibandronic acid in patients with various degrees of renal impairment is linearly related to creatinine clearance (CLcr). 
Renalni očistek ibandronske kisline pri bolnikih z različnimi stopnjami ledvične okvare je v linearni odvisnosti od kreatininskega očistka (CLcr).
At 12 months median relative changes from baseline were -58.6 % for the intravenous injection of 3 mg every 3 months regimen and -62.6 % for oral 2.5 mg daily regimen. 
Po 12 mesecih je bila mediana relativne spremembe od izhodiščne vrednosti -58,6 % za odmerjanje 3 mg v obliki intravenskih injekcij vsake 3 mesece in -62,6 % za peroralno odmerjanje 2,5 mg na dan.
Colourless, clear solution. 
Je brezbarvna, bistra raztopina.
Due to the limited data available, ibandronic acid should not be used in all patients with end-stage renal disease. 
Zaradi omejenih podatkov ibandronske kisline pri bolnikih s končno ledvično odpovedjo ne smemo uporabljati.
Less frequently, a decrease in serum calcium below normal range (hypocalcaemia) is reported. 
Manj pogosto poročajo o znižanju serumskega kalcija pod spodnjo mejo normale
Subjects with severe renal impairment (CLcr less than 30 ml/min) receiving daily oral administration of 10 mg ibandronic acid for 21 days, had 2 - 3 fold higher plasma concentrations than subjects with normal renal function and total clearance of ibandronic acid was 44 ml/min. 
Bolniki s hudo motnjo ledvičnega delovanja (CLcr manjši kot 30 ml/min), ki so prejemali peroralno 10 mg ibandronske kisline na dan 21 dni, so imeli 2- do 3-krat višje plazemske koncentracije kot osebe z normalno ledvično funkcijo.
After intravenous administration of 0.5 mg of ibandronic acid, total, renal, and non-renal clearances decreased by 67 %, 77 % and 50 %, respectively, in subjects with severe renal failure, but there was no reduction in tolerability associated with the increase in exposure. 
Po intravenskem dajanju 0,5 mg ibandronske kisline se je pri bolnikih s hudo motnjo ledvičnega delovanja celokupni očistek zmanjšal za 67 %, ledvični očistek za 77 %, neledvični očistek pa za 50 %.
• pain in your muscles, joints, or back 
• bolečina v mišicah sklepih ali hrbtu,
radiotherapy to bone for treatment of fractures/impending fractures surgery to bone for treatment of fractures vertebral fractures non-vertebral fractures. 
zdravljenje kosti z obsevanjem zaradi fraktur/pretečih fraktur, operacija kosti za zdravljenje fraktur, vertebralne frakture,
Table 4: Results from 3 years fracture study MF 4411 (%, 95 % CI) for patients with lumbar spine BMD T-score below -2.5 at baseline 
Preglednica 4: Rezultati 3-letne študije zlomov MF 4411 (%, 95-% interval zaupanja) za bolnike, ki so imeli na začetku zdravljenja T-vrednost MKG ledvene hrbtenice pod -2,5.
Based on the results of study BM 16550, ibandronic acid 3 mg intravenous injection, administered every 3 months is expected to be at least as effective in preventing fractures as the oral regimen of ibandronic acid 2.5 mg daily. 
Glede na rezultate študije BM 16550 pričakujemo, da je ibandronska kislina 3 mg v obliki intravenske injekcije, ki jo dajemo vsake 3 mesece, najmanj enako učinkovita v preprečevanju zlomov kakor peroralno odmerjena ibandronska kislina 2,5 mg enkrat na dan.
Due to limited clinical experience, ibandronic acid injection is not recommended for patients with a serum creatinine above 200 μmol/l (2.3 mg/dl) or with a creatinine clearance below 30 ml/min (see section 4.2 and section 5.2). 
Zaradi omejenih kliničnih izkušenj ibandronske kisline v obliki injekcije ne priporočamo bolnikom, ki imajo serumski kreatinin nad 200 µmol/l (2,3 mg/dl) ali kreatininski očistek, manjši kot 30 ml/min (glejte poglavje 4.2 in poglavje 5.2).
Secondary efficacy endpoints 
Sekundarni cilj raziskave učinkovitosti
Daily oral treatment with ibandronic acid 2.5 mg tablets resulted in progressive increases in BMD at vertebral and nonvertebral sites of the skeleton. 
Peroralno zdravljenje z 2,5-mg tabletami ibandronske kisline enkrat na dan je povzročilo progresivno povišanje MKG vretenc in nevretenčnih delov skeleta.
Ibandronic acid Accord 2 mg and 6 mg concentrate for solution for infusion (for oncology indications) 
Ibandronska kislina Accord 2 mg in 6 mg koncentrat za raztopino za infundiranje (za onkološke indikacije)
Studies in rats have shown some reproductive toxicity (see section 5.3). 
Študije na podganah so pokazale določen vpliv na sposobnost razmnoževanja (glejte poglavje 5.3).
In the pivotal two-year study in postmenopausal women with osteoporosis (BM16550), the overall safety of intravenous injection of ibandronic acid 3 mg every 3 months and oral ibandronic acid 2.5 mg daily were shown to be similar. 
V ključni dveletni študiji pri ženskah z osteoporozo v postmenopavzi (BM 16550) je bila celokupna varnost ibandronske kisline 3 mg v obliki intravenske injekcije, dane vsake 3 mesece, in ibandronske kisline 2,5 mg, dane peroralno enkrat na dan, podobna.
Solution for injection 1 pre-filled syringe + 1 injection needle 4 pre-filled syringes + 4 injection needles 
1 napolnjena injekcijska brizga + 1 injekcijska igla 4 napolnjene injekcijske brizge + 4 injekcijske igle
Independent risk factors, for example, low BMD, age, the existence of previous fractures, a family history of fractures, high bone turnover and low body mass index should be considered in order to identify women at increased risk of osteoporotic fractures. 
Pri prepoznavanju žensk s povečanim tveganjem za osteoporotični zlom moramo upoštevati neodvisne dejavnike tveganja, kot so na primer nizka mineralna kostna gostota, starost, obstoj predhodnih zlomov, družinska obremenjenost z zlomi, visoko razmerje med razgradnjo in tvorbo kosti in nizek indeks telesne mase.
Prior to treatment with Ibandronic acid Accord the patient should be adequately rehydrated with 9 mg/ml (0.9 %) sodium chloride. 
Pred začetkom zdravljenja z zdravilom Ibandronska kislina Accord je potrebna zadostna rehidracija bolnika z natrijevim kloridom 9 mg/ml (0,9 %).
Plasma concentrations of ibandronic acid increase in a dose-proportional manner after intravenous administration of 0.5 mg to 6 mg. 
Plazemske koncentracije ibandronske kisline se po intravenskem dajanju 0,5 mg do 6 mg povečujejo sorazmerno z odmerkom.
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 6 mg/6 ml 
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT 6 mg/6 ml
There is no evidence that ibandronic acid is metabolised in animals or humans. 
Ni dokazov, da bi se ibandronska kislina pri ljudeh in živalih presnavljala.
Hypocalcaemia and other disturbances of bone and mineral metabolism should be assessed and effectively treated before starting Ibandronic acid Accord injection therapy. 
Hipokalcemijo in druge motnje v kosteh in presnovi mineralov moramo prepoznati in učinkovito zdraviti pred začetkom intravenskega zdravljenja z zdravilom Ibandronska kislina Accord.
Early plasma levels fall quickly, reaching 10 % of the peak values within 3 and 8 hours after intravenous or oral administration, respectively. 
Zgodnje plazemske koncentracije hitro padejo, 10 % največje vrednosti dosežejo 3 ure po intravenskem in 8 ur po peroralnem dajanju.
What you need to know before you receive Ibandronic acid Accord 3. 
Kaj morate vedeti, preden boste prejeli zdravilo Ibandronska kislina Accord 3.
Do not use this medicine after the expiry date which is stated on the carton and on the label after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in nalepki poleg oznake EXP. Rok uporabnosti zdravila se izteče na zadnji dan navedenega meseca.
INFORMATION IN BRAILLE [Justification for not including Braille accepted] 
PODATKI V BRAILLOVI PISAVI Sprejeta je utemeljitev, da Braillova pisava ni potrebna.
Ibandronic acid is only for use in postmenopausal women and must not be taken by women of child bearing potential. 
Ibandronsko kislino lahko uporabljajo samo ženske v postmenopavzi, ženske v rodni dobi pa ga ne smejo uporabljati.
After that, go back to getting the injections every 3 months from the date of the most recent injection. 
Po tem se vrnite na običajno shemo odmerjanja, ki je vsake 3 mesece od dneva zadnje injekcije.
• hair loss 
• izguba las;
Most cases of adverse reactions did not lead to cessation of therapy. 
V večini primerov prekinitev terapije zaradi neželenih učinkov ni bila potrebna.
Any unused solution for injection, syringe and injection needle should be disposed of in accordance with local requirements. 
Neuporabljeno raztopino za injekcije, injekcijske brizge in injekcijske igle zavrzite v skladu z lokalnimi predpisi.
Each ml of solution contains 1 mg ibandronic acid. 
En ml raztopine vsebuje 1 mg ibandronske kisline.
Excipients with known effect This medicinal product contains less than 1 mmol sodium (23 mg) per vial, i.e. essentially sodium free. 
Pomožne snovi z znanim učinkom Zdravilo vsebuje manj kot 1 mmol natrija (23 mg) na vialo, kar v bistvu pomeni brez natrija.
See section 4. 
Preglednica 3.
• pain or sore in your mouth or jaw. 
• bolečina ali rana v vaših ustih ali čeljusti.
Gastritis, Dyspepsia, Diarrhoea, Abdominal pain, Nausea, Constipation 
Bolezni prebavil gastritis, dispepsija, diareja, abdominalna bolečina, navzea, zaprtje
What you need to know before you receive Ibandronic acid Accord 
Kaj morate vedeti, preden boste prejeli zdravilo Ibandronska kislina Accord
• inflammation of a vein 
• vnetje vene,
Ibandronic acid concentrate for solution for infusion should be administered as an intravenous infusion over 2 hours. 
Koncentrat ibandronske kisline za raztopino za infundiranje je treba aplicirati v obliki intravenske infuzije 2 uri.
Ibandronic acid Accord may help lower the chances of breaking bones (fractures). 
Zdravilo Ibandronska kislina Accord pomaga zmanjšati možnost zloma.
There is no evidence for any clinically relevant inter-ethnic differences between Asians and Caucasians in ibandronic acid disposition. 
Za klinično pomembne medetnične razlike v razpoložljivosti ibandronske kisline med Azijci in Kavkazijci ni dokazov.
• not enough calcium and vitamin D in the diet 
• premajhen vnos kalcija in vitamina D s hrano,
• walking or other weight-bearing exercise 
• hojo ali druge telesne aktivnosti z vplivom na telesno maso,
The recommended dose of ibandronic acid is 3 mg, administered as an intravenous injection over 1530 seconds, every three months. 
Priporočeni odmerek ibandronske kisline je 3 mg v obliki intravenske injekcije, ki jo dajemo 15 do 30 sekund, vsake 3 mesece.
Clinical studies in the prevention of skeletal events in patients with breast cancer and bone metastases 
Klinične študije preprečevanja z okostjem povezanih dogodkov pri bolnikih z rakom dojke in metastazami v kosteh
For the prevention of skeletal events in patients with breast cancer and bone metastases, the Ibandronic acid Accord infusion is repeated at 3-4 week intervals. 
Za preprečevanje z okostjem povezanih dogodkov pri bolnikih z rakom dojke in metastazami v kosteh infuzijo zdravila Ibandronska kislina Accord ponovimo v 3- do 4-tedenskih intervalih.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 Hypocalcaemia 
Preobčutljivost na zdravilno učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1
This is because aminoglycosides and Ibandronic acid Accord can both lower the amount of calcium in your blood. 
Aminoglikozidi in zdravilo Ibandronska kislina Accord lahko znižajo koncentracijo kalcija v krvi.
2 mg 4 mg 6 mg For these patients and dosages, the median time to achieve normocalcaemia was 4 to 7 days. 
Za te bolnike je bila pri teh odmerkih mediana časa do normokalciemije 4 do 7 dni.
Prior to treatment with ibandronic acid the patient should be adequately rehydrated with 9 mg/ml (0.9%) sodium chloride solution. 
Pred zdravljenjem z ibandronsko kislino izvedemo ustrezno hidracijo bolnika z raztopino natrijevega klorida 9 mg/ml (0,9 %).
Overhydration should be avoided in patients at risk of cardiac failure. 
Pri bolnikih, pri katerih obstaja tveganje za srčno popuščanje, se je treba izogibati pretirani hidraciji.
Table 2 Efficacy Results (Breast Cancer Patients with Metastatic Bone Disease) 
Rezultati učinkovitosti (bolniki z rakom dojke in metastatično boleznijo kosti)
Paediatric population (see section 4.2 and section 5.1) 
Pediatrična populacija (glejte poglavji 4.2 in 5.1)
6 ml, glass vial (type I) with ethylene tetrafluoroethylene rubber stopper and aluminium seals with pink flip-off cap. 
6 ml viala iz stekla (tipa I) z etilen tetrafluoroetilenskim gumijastim zamaškom in aluminijastim pokrovčkom s »flip-off« zaporko v roza barvi.
After dilution: 
Po razredčitvi:
Where the medicinal product is administered into an existing intravenous infusion line, the infusate should be restricted to either isotonic saline or 50 mg/ml (5 %) glucose solution. 
Kadar se zdravilo daje v obstoječe intravenske infuzijske kanale, je infuzat lahko le izotonična raztopina natrijevega klorida ali 50 mg/ml (5-%) raztopina glukoze.
Each pre-filled syringe contains 3 ml of solution. 
Ena napolnjena injekcijska brizga vsebuje 3 ml raztopine.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. 
Druga zdravila in zdravilo Ibandronska kislina Accord Obvestite svojega zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
Ibandronic acid injection is not recommended for use in patients who have a serum creatinine above 200 μmol/l (2.3 mg/dl) or who have a creatinine clearance (measured or estimated) below 30 ml/min, because of limited clinical data available from studies including such patients (see section 4.4 and section 5.2) 
Uporaba ibandronske kisline v obliki injekcije pri bolnikih s serumskim kreatininom nad 200 µmol/l (2,3 mg/dl) ali s kreatininskim očistkom (izmerjenim ali ocenjenim) pod 30 ml/min zaradi malo kliničnih podatkov iz študij, ki so vključevale take bolnike, ni priporočljiva (glejte poglavji 4.4 in 5.2).
Ibandronic acid 2.5 mg daily tablets 
Ibandronska kislina, 2,5-mg tableta, enkrat na dan
Care must be taken not to administer ibandronic acid injection via intra-arterial or paravenous administration as this could lead to tissue damage. 
Potrebna je previdnost, da injekcije ibandronske kisline ne damo intraarterijsko ali paravensko, ker lahko poškodujemo tkivo.
Elderly population (see section 4.2) 
Starejši bolniki (glejte poglavje 4.2)
Ibandronic acid Accord 3 mg solutionfor injection (for osteoporosos indications) Medicinal product subject to medical prescription. 
Ibandronska kislina Accord 3 mg raztopina za injiciranje (za indikacije, povezane z osteoporozo) Predpisovanje in izdaja zdravila je le na recept.
(dead bone tissue) in the jaw bone). 
(nekrozo (mrtvo kostno tkivo) v čeljustnicah);
Ibandronic acid solution for injection must not be mixed with calcium-containing solutions or other intravenously administered medicinal products. 
Raztopine ibandronske kisline za injiciranje ne smemo mešati z raztopinami, ki vsebujejo kalcij, ali drugimi intravensko dajanimi zdravili.
Excipient with known effect Ibandronic acid injection is essentially sodium free. 
Pomožna snov z znanim učinkom Zdravilo Ibandronska kislina Accord je praktično brez natrija.
The pharmacokinetics of ibandronic acid in patients with end-stage renal disease was only assessed in a small number of patients managed by haemodialysis, therefore, the pharmacokinetics of ibandronic acid in the patients not undergoing haemodialysis is unknown. 
Farmakokinetiko ibandronske kisline pri bolnikih s končno ledvično odpovedjo so proučevali le pri majhnem številu bolnikov, ki so se zdravili s hemodializo.
Tell your doctor, nurse or pharmacist if you are taking, have recently taken or might take any other medicines. 
Druga zdravila in zdravilo Ibandronska kislina Accord Obvestite zdravnika, medicinsko sestro ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
A dental examination with preventive dentistry and an individual benefit-risk assessment is recommended prior to treatment with ibandronic acid in patients with concomitant risk factors. 
Pri bolnikih s sočasnimi dejavniki tveganja je priporočljivo, da se pred začetkom zdravljenja z ibandronsko kislino opravita zobozdravstveni pregled in individualna ocena koristi in tveganja.
Where Ibandronic acid Accord is administered via an existing intravenous infusion line, the intravenous infusate should be restricted to either isotonic saline or 50 mg/ml (5 %) glucose solution. 
Kjer zdravilo Ibandronska kislina Accord dajemo skozi obstoječi intravenski infuzijski kanal, je intravenski infuzat lahko le izotonična raztopina natrijevega klorida ali 50 mg/ml (5-%) raztopina glukoze.
• fluid in your lungs 
• nabiranje tekočine v pljučih;
Ibandronic acid Accord 3 mg solution for injection in pre-filled syringe like other bisphosphonates administered intravenously, may cause a transient decrease in serum calcium values. 
Ibandronska kislina Accord 3 mg raztopina za injiciranje v napolnjeni injekcijski brizgi lahko kot drugi intravensko dajani difosfonati povzroči prehodno zmanjšanje koncentracije kalcija v serumu.
Packs of 1 pre-filled syringe and 1 injection needle or 4 pre-filled syringes and 4 injection needles. 
Na voljo je pakiranje po 1 napolnjeno injekcijsko brizgo in 1 injekcijsko iglo ali po 4 napolnjene injekcijske brizge in 4 injekcijske igle.
For treatment of tumour induced hypercalcaemia, Ibandronic acid Accord concentrate for solution for infusion is generally given as a single infusion. 
Za zdravljenje tumorsko povzročene hiperkalciemije običajno dajemo koncentrat za raztopino za infundiranje Ibandronska kislina Accord kot enkratno infuzijo.
• kidney cyst(fluid-filled sac in the kidney) 
• ledvična cista (vrečka v ledvicah napolnjena s tekočino).
This medicine contains less than 1 mmol sodium (23 mg) per vial, i.e. ‘essentially sodium free'. 
To zdravilo vsebuje manj kot 1 mmol natrija (23 mg) na vialo, kar v bistvu pomeni "brez natrija".